Literature DB >> 7621683

Metabolic parameter, bleeding, and weight changes in U.S. women using progestin only contraceptives.

R Mainwaring1, H A Hales, K Stevenson, H H Hatasaka, A M Poulson, K P Jones, C M Peterson.   

Abstract

Our objective was to determine the effect of progestin-only contraceptives on metabolic parameters, bleeding patterns, and weight changes during the first year of use. Seventy-one women (> 95% Caucasian), who were advised regarding contraception alternatives, self-selected levonorgestrel implants (n = 44), depo-medroxyprogesterone acetate (n = 22), or oral norethindrone (n = 5). One year later, 11 levonorgestrel implant and five depomedroxyprogesterone acetate patients were randomly selected to compare (pre- and post-progestin use) levels of cholesterol, triglycerides, low density lipoprotein (LDL), high density lipoprotein (HDL), very low density lipoprotein (VLDL), apolipoproteins A-1 and B-100, bilirubin, and sex hormone binding globulin. Monthly bleeding and spotting records were kept in each group. Body weights were also monitored in each group. No statistically significant differences in metabolic parameters were found between pre- and post-progestin use in the levonorgestrel implant and depo-medroxyprogesterone acetate groups. Continued bleeding patterns were more prominent in the levonorgestrel implant and oral norethindrone groups than in patients receiving depo-medroxyprogesterone acetate. No significant weight gain was detected in any group. No changes in metabolic parameters or weight were noted over the one year of use of levonorgestrel implants or depo-medroxyprogesterone acetate. Depo-medroxyprogesterone acetate had the highest incidence of amenorrhea.

Entities:  

Keywords:  Americas; Biology; Bleeding; Body Weight--changes; Clinical Research; Contraception; Contraceptive Agents; Contraceptive Agents, Female; Contraceptive Agents, Progestin; Contraceptive Implants; Contraceptive Methods; Depo-provera; Developed Countries; Diseases; Family Planning; Levonorgestrel; Medroxyprogesterone Acetate; Menstruation Disorders; Metabolic Effects; Norethindrone; North America; Northern America; Oral Contraceptives; Physiology; Progestins, Low-dose; Research Report; Signs And Symptoms; United States; Utah

Mesh:

Substances:

Year:  1995        PMID: 7621683     DOI: 10.1016/0010-7824(95)00011-x

Source DB:  PubMed          Journal:  Contraception        ISSN: 0010-7824            Impact factor:   3.375


  1 in total

1.  Prospective study of weight change in new adolescent users of DMPA, NET-EN, COCs, nonusers and discontinuers of hormonal contraception.

Authors:  Mags E Beksinska; Jenni A Smit; Immo Kleinschmidt; Cecilia Milford; Timothy M M Farley
Journal:  Contraception       Date:  2010-01       Impact factor: 3.375

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.